193 related articles for article (PubMed ID: 30066906)
1. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
4. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Li N; Li H; Su F; Li J; Ma X; Gong P
Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
[TBL] [Abstract][Full Text] [Related]
5. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
7. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
11. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
12. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
13. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
16. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
[TBL] [Abstract][Full Text] [Related]
17. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
19. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
20. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
